Furine and Pyrimidine Enzymic Programs and Nucleotide Pattern in Sarcoma1

Total Page:16

File Type:pdf, Size:1020Kb

Furine and Pyrimidine Enzymic Programs and Nucleotide Pattern in Sarcoma1 [CANCER RESEARCH 43. 1019-1023, March 1983] 0008-5472/83/0043-0000$02.00 Furine and Pyrimidine Enzymic Programs and Nucleotide Pattern in Sarcoma1 George Weber,2 Michael E. Burt, Robert C. Jackson, Noemi Prajda, May S. Lui, and Eiji Takeda Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis, Indiana 46223 [G. W., R. C. J., N. P., M. S. L., E. T.], and the Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20205 [M. E. B.] ABSTRACT 4.5- to 12-fold. The cytidine triphosphate concentration in creased 17-fold. In the muscle, the concentrations of cytidine The purpose of this study was to elucidate the enzymic diphosphate, inosine monophosphate, and xanthosine mono- program and nucleotide pattern of a chemically induced, trans- phosphate were too low for the sensitivity of our method to plantable sarcoma and to compare the biochemical makeup detect, but these pools were well measurable in the sarcoma. with that of normal and differentiating skeletal muscle in the The enzymic program of sarcoma was distinguished from rat. that of the muscle of 6-day-old rats by the quantitatively more The activities of 28 key enzymes of pyrimidine, purine, and pronounced alterations in the sarcoma. The activities of uridine carbohydrate metabolism were determined in the 100,000 x phosphorylase, hexokinase, 6-phosphogluconate dehydroge- g supernatant fluid or in purified extracts. The concentrations nase, and adenosine deaminase were higher in sarcoma but of the adenosine, guanosine, uridine, and cytidine mono-, di-, were lower or not significantly altered in 6-day-old muscle as and triphosphates were measured by high-pressure liquid chro- compared to activities of adult muscle. The activities of aden matography of samples prepared by the freeze-clamp method. osine monophosphate deaminase and xanthine oxidase de The results of enzymic and metabolite assays were given in creased in sarcoma, whereas they were unchanged or in nmol/hr/mg protein and nmol/g, respectively, and for com creased, respectively, in 6-day-old muscle. parability were also expressed as percentages of the muscle In the sarcoma, important segments of alterations in enzy- of adult rat as the reference normal tissue in this study. These mology of carbohydrate, purine, and pyrimidine metabolism percentages denote that the activities in sarcoma or in differ were identified that proved to be a program shared with that entiating muscle were higher or lower than those in the muscle observed in chemically induced and virus-derived transplanta- of adult rats. ble rat and avian hepatocellular carcinomas and in primary In pyrimidine metabolism, the specific activities of cytidine human liver, kidney, and colon neoplasms. There were also diphosphate reducíase, cytidine triphosphate synthetase, and sarcoma-specific markers in the enzymic programs and nu thymidine kinase increased in the sarcoma 60-, 78-, and 80- cleotide patterns that readily distinguish this tumor from other fold over those of the muscle. The activities of the key glycolytic examined neoplasms. enzymes, hexokinase and phosphofructokinase, increased 7- The present investigation revealed a formidable biochemical and 3-fold, whereas that of pyruvate kinase decreased to 35%. capacity for replication in the sarcoma cells. These biochemical The activities of glucose-6-phosphatase and fructose-1,6-di- studies also point out possible targets in the strategy of anti- phosphatase declined to 42 and 48%, respectively. The activ cancer drug treatment of sarcoma. ities of enzymes involved in pentose phosphate production and utilization increased, with that of the glucose-6-phosphate de- INTRODUCTION hydrogenase being elevated 288-fold. The activity of galacto- kinase was unchanged, whereas that of uridine diphosphoglu- Previous work in this laboratory demonstrated, in a spectrum cose pyrophosphorylase decreased to 22%. In purine metab of chemically induced, transplantable hepatocellular carcino olism, the activities of the first three enzymes of guanosine mas of the liver, a transformation- and progression-linked im triphosphate biosynthesis, inosine monophosphate dehydro- balance in the activities of key enzymes of carbohydrate, purine, and pyrimidine metabolism and in the pattern of ribo- genase, guanosine monophosphate synthetase, and guanosine monophosphate kinase, increased 22-, 2-, and 5-fold, respec nucleotides and deoxyribonucleoside triphosphates (3, 9, 10). tively. In contrast, the activities of adenylosuccinate lyase and Subsequent studies indicated the presence of the metabolic adenosine monophosphate deaminase decreased to 28 and imbalance in a series of carcinomas of kidney and colon in the 42%. The activities of adenosine deaminase and kinase in rat and mouse and, recently, in human renal and colon carci creased 1.8- and 3.5-fold. The activity of the rate-limiting nomas (1,2,12). The purpose of the present investigation was enzyme of de novo inosine monophosphate biosynthesis, ami- to answer the following questions. Is the biochemical imbalance dotransferase, increased 13-fold, whereas that of the rate- discovered in carcinomas applicable to sarcoma? Are the limiting purine-catabolic enzyme, xanthine oxidase, decreased enzymic indications of an imbalance in the cellular metabolic to 54%. programs verifiable by the pattern of nucleotides in sarcoma? In the sarcoma, the concentrations of adenosine tri-, di-, and Is the biochemical pattern of the sarcoma different from that of monophosphate decreased to 24, 49, and 76%. In contrast, differentiating muscle? Is it possible to identify a shared pattern the pools of guanosine tri-, di-, and monophosphate increased of biochemical imbalance in carcinomas and sarcoma? Are 9- to 11-fold, and those of the uridylates were also elevated there any sarcoma-specific biochemical alterations? 1This investigation was supported by USPHS Grants CA-13526, CA-05034. MATERIALS AND METHODS and CA-10792. 2 To whom requests for reprints should be addressed. For these studies, a methylcholanthrene-induced sarcoma line car Received July 22, 1982; accepted December 3, 1982. ried in male Fischer (F344) rats (Charles River Laboratories, Portage, MARCH 1983 1019 Downloaded from cancerres.aacrjournals.org on September 27, 2021. © 1983 American Association for Cancer Research. G. Weber et al. Mich.) and skeletal muscles from control, normal rats of the same sex, In the sarcoma, the activities of all synthetic enzymes ex strain, age, and weight were used. The tumor was a rhabdomyosar- amined were very markedly increased as compared to muscle, coma; the induction, maintenance, histology, and biological behavior ranging from a rise of 78- to 80-fold for thymidine kinase and are described in detail elsewhere.3 This is a fairly rapidly growing CTP synthetase to increases of 26- and 14-fold for uridine neoplasm which resembles the macroscopic appearance and growth kinase and uracil phosphoribosyltransferase. These elevations rate of hepatoma 3924A and reaches a diameter of 1.5 cm in about 14 were much more marked (about 10-fold higher) than were days, with death occurring 30 to 34 days after inoculation. The 12- to 18-day-old tumor has no necrosis, and it is well suited for the metabolic those observed in the rapidly growing liver tumors compared to the resting liver (16). studies that were conducted. The animals were inoculated s.c. by injection of 106 viable tumor In carbohydrate metabolism in the muscle, the activities of cells, and 1 week later the tumor-bearing and control rats were shipped the key glycolytic enzymes, hexokinase, phosphofructokinase, by air from the National Cancer Institute to Indiana University. All rats and pyruvate kinase, were higher than those in rat liver (11). were housed in individual cages in air-conditioned rooms, which were This is expected in view of the well-known glycolytic capacity illuminated daily from 6 a.m. to 7 p.m. Purina laboratory chow and of skeletal muscle. In the sarcoma, the activities of phospho water were available ad libitum. Rats were always killed between 9 and fructokinase and hexokinase increased 3- to 7-fold, which is in 10 a.m. line with observations made in hepatic carcinomas of similar Biochemical Methods. Animals were stunned, decapitated, and rapid growth rates (11 ). In contrast to results in hepatomas, bled; tumors were excised, and 10% homogenates were prepared in the appropriate media as reported earlier (1, 2, 13). For the freeze- the activity of pyruvate kinase, which is orders of magnitude higher than any other enzyme that we have studied, was clamp studies, the animals received light ether anesthesia, and tumors decreased to one-third of that observed in the control muscle. and muscles were removed as described elsewhere (1 7). Preparation of the extracts and methods for measurement of en In muscle, the gluconeogenic enzymes, glucose-6-phospha- zymes were described in detail elsewhere (1, 2, 5, 13). Preliminary tase and fructose-1,6-diphosphatase, were present only in low kinetic studies were carried out to ensure that the enzyme assays were activities, which were further decreased to 42 to 48% in the conducted under linear kinetic conditions, at optimum substrate and sarcoma. These results are in line with the decline in activities activator concentrations, and that the activities measured were pro of gluconeogenic enzymes first reported in hepatomas (11 ). portionate with the amount of enzyme added and reaction time elapsed. In pentose phosphate metabolism in the muscle, the activity
Recommended publications
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • Purine Metabolism in Cultured Endothelial Cells
    PURINE METABOLISM IN MAN-III Biochemical, Immunological, and Cancer Research Edited by Aurelio Rapado Fundacion Jimenez Diaz Madrid, Spain R.W.E. Watts M.R.C. Clinical Research Centre Harrow, England and Chris H.M.M. De Bruyn Department of Human Genetics University of Nijmegen Faculty of Medicine Nijmegen, The Netherlands PLENUM PRESS · NEW YORK AND LONDON Contents of Part Β I. PURINE METABOLISM PATHWAYS AND REGULATION A. De Novo Synthesis; Precursors and Regulation De Novo Purine Synthesis in Cultured Human Fibroblasts 1 R.B. Gordon, L. Thompson, L.A. Johnson, and B.T. Emmerson Comparative Metabolism of a New Antileishmanial Agent, Allopurinol Riboside, in the Parasite and the Host Cell 7 D. J. Nelson, S.W. LaFon, G.B. Elion, J.J. Marr, and R.L. Berens Purine Metabolism in Rat Skeletal Muscle 13 E. R. Tully and T.G. Sheehan Alterations in Purine Metabolism in Cultured Fibroblasts with HGPRT Deficiency and with PRPPP Synthetase Superactivity 19 E. Zoref-Shani and 0. Sperling Purine Metabolism in Cultured Endothelial Cells 25 S. Nees, A.L. Gerbes, B. Willershausen-Zönnchen, and E. Gerlach Determinants of 5-Phosphoribosyl-l-Pyrophosphate (PRPP) Synthesis in Human Fibroblasts 31 K.0, Raivio, Ch. Lazar, H. Krumholz, and M.A. Becker Xanthine Oxidoreductase Inhibition by NADH as a Regulatory Factor of Purine Metabolism 35 M.M. Jezewska and Z.W. Kaminski vii viii CONTENTS OF PART Β Β. Nucleotide Metabolism Human Placental Adenosine Kinase: Purification and Characterization 41 CM. Andres, T.D. Palella, and I.H. Fox Long-Term Effects of Ribose on Adenine Nucleotide Metabolism in Isoproterenol-Stimulated Hearts .
    [Show full text]
  • Metabolism of Purines and Pyrimidines in Health and Disease
    39th Meeting of the Polish Biochemical Society Gdañsk 16–20 September 2003 SESSION 6 Metabolism of purines and pyrimidines in health and disease Organized by A. C. Sk³adanowski, A. Guranowski 182 Session 6. Metabolism of purines and pyrimidines in health and disease 2003 323 Lecture The role of DNA methylation in cytotoxicity mechanism of adenosine analogues in treatment of leukemia Krystyna Fabianowska-Majewska Zak³ad Chemii Medycznej IFiB, Uniwersytet Medyczny, ul. Mazowiecka 6/8, 92 215 £ódŸ Changes in DNA methylation have been recognized tory effects of cladribine and fludarabine on DNA as one of the most common molecular alterations in hu- methylation, after 48 hr growth of K562 cells with the man neoplastic diseases and hypermethylation of drugs, are non-random and affect mainly CpG rich is- gene-promoter regions is one of the most frequent lands or CCGG sequences but do not affect sepa- mechanisms of the loss of gene functions. For this rea- rately-located CpG sequences. The analysis showed son, DNA methylation may be a tool for detection of that cladribine (0.1 mM) reduced the methylated early cell transformations as well as predisposition to cytosines in CpG islands and CCGG sequences to a sim- metastasis process. Moreover, DNA methylation seems ilar degree. The inhibition of cytosine methylation by to be a promissing target for new preventive and thera- fludarabine (3 mM) was observed mainly in CCGG se- peutic strategies. quences, sensitive to HpaII, but the decline in the meth- Our studies on DNA methylation and cytotoxicity ylated cytosine, located in CpG island was 2-fold lower mechanism of antileukemic drugs, cladribine and than that with cladribine.
    [Show full text]
  • Determining HDAC8 Substrate Specificity by Noah Ariel Wolfson A
    Determining HDAC8 substrate specificity by Noah Ariel Wolfson A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Biological Chemistry) in the University of Michigan 2014 Doctoral Committee: Professor Carol A. Fierke, Chair Professor Robert S. Fuller Professor Anna K. Mapp Associate Professor Patrick J. O’Brien Associate Professor Raymond C. Trievel Dedication My thesis is dedicated to all my family, mentors, and friends who made getting to this point possible. ii Table of Contents Dedication ....................................................................................................................................... ii List of Figures .............................................................................................................................. viii List of Tables .................................................................................................................................. x List of Appendices ......................................................................................................................... xi Abstract ......................................................................................................................................... xii Chapter 1 HDAC8 substrates: Histones and beyond ...................................................................... 1 Overview ..................................................................................................................................... 1 HDAC introduction
    [Show full text]
  • Metabolomics Identifies Pyrimidine Starvation As the Mechanism of 5-Aminoimidazole-4-Carboxamide-1- Β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
    Published OnlineFirst April 12, 2013; DOI: 10.1158/1535-7163.MCT-12-1042 Molecular Cancer Cancer Therapeutics Insights Therapeutics Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1- b-Riboside-Induced Apoptosis in Multiple Myeloma Cells Carolyne Bardeleben1, Sanjai Sharma1, Joseph R. Reeve3, Sara Bassilian3, Patrick Frost1, Bao Hoang1, Yijiang Shi1, and Alan Lichtenstein1,2 Abstract To investigate the mechanism by which 5-aminoimidazole-4-carboxamide-1-b-riboside (AICAr) induces apoptosis in multiple myeloma cells, we conducted an unbiased metabolomics screen. AICAr had selective effects on nucleotide metabolism, resulting in an increase in purine metabolites and a decrease in pyrimidine metabolites. The most striking abnormality was a 26-fold increase in orotate associated with a decrease in uridine monophosphate (UMP) levels, indicating an inhibition of UMP synthetase (UMPS), the last enzyme in the de novo pyrimidine biosynthetic pathway, which produces UMP from orotate and 5-phosphoribosyl- a-pyrophosphate (PRPP). As all pyrimidine nucleotides can be synthesized from UMP, this suggested that the decrease in UMP would lead to pyrimidine starvation as a possible cause of AICAr-induced apoptosis. Exogenous pyrimidines uridine, cytidine, and thymidine, but not purines adenosine or guanosine, rescued multiple myeloma cells from AICAr-induced apoptosis, supporting this notion. In contrast, exogenous uridine had no protective effect on apoptosis resulting from bortezomib, melphalan, or metformin. Rescue resulting from thymidine add-back indicated apoptosis was induced by limiting DNA synthesis rather than RNA synthesis. DNA replicative stress was identified by associated H2A.X phosphorylation in AICAr-treated cells, which was also prevented by uridine add-back.
    [Show full text]
  • TITLE Adenylate Kinase 2 Deficiency Causes NAD+ Depletion and Impaired Purine Metabolism During Myelopoiesis
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.05.450633; this version posted July 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. TITLE Adenylate Kinase 2 deficiency causes NAD+ depletion and impaired purine metabolism during myelopoiesis AUTHORS Wenqing Wang1, Andew DeVilbiss2, Martin Arreola1, Thomas Mathews2, Misty Martin-Sandoval2, Zhiyu Zhao2, Avni Awani1, Daniel Dever1, Waleed Al-Herz3, Luigi Noratangelo4, Matthew H. Porteus1, Sean J. Morrison2, Katja G. Weinacht1, * 1. Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305 USA 2. Children’s Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390 USA 3. Department of Pediatrics, Faculty of Medicine, Kuwait University, Safat, 13110 Kuwait 4. Laboratory of Clinical Immunology and Microbiology, National Institute of Health, BETHESDA MD 20814 USA * Corresponding author ABSTRACT Reticular Dysgenesis is a particularly grave from of severe combined immunodeficiency (SCID) that presents with severe congenital neutropenia and a maturation arrest of most cells of the lymphoid lineage. The disease is caused by biallelic loss of function mutations in the mitochondrial enzyme Adenylate Kinase 2 (AK2). AK2 mediates the phosphorylation of adenosine monophosphate (AMP) to adenosine diphosphate (ADP) as substrate for adenosine triphosphate (ATP) synthesis in the mitochondria. Accordingly, it has long been hypothesized that a decline in OXPHOS metabolism is the driver of the disease. The mechanistic basis for Reticular Dysgenesis, however, remained incompletely understood, largely due to lack of appropriate model systems to phenocopy the human disease.
    [Show full text]
  • Adenosine Deaminase (ADA) Isoenzymes ADA1 and ADA2 in Biological Fluids
    Eur Respir J 1997; 10: 2186–2187 Copyright ERS Journals Ltd 1997 DOI: 10.1183/09031936.97.10092186 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 CORRESPONDENCE Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2 in biological fluids To the Editor: readily obtained by measuring total ADA and the ADA2 which is not inhibited by 100 mmol·L-1 of added EHNA. We read with great interest the editorial by GAKIS [1] In fact, this method is being increasingly used by acquired about the extreme importance of the adenosine deami- immune deficiency syndrome (AIDS) researchers since nase (ADA) isoenzymes ADA1 and ADA2 on the some authors have reported a higher serum ADA activ- homeostasis of 2' deoxyadenosine and adenosine, espe- ity in human immunodeficiency virus (HIV)-1 positive cially when monocytes and macrophages are infected patients [4]. By the method we propose, some authors by intracellular microorganisms. Serum ADA activity have found that ADA2 isoenzyme activity is of con- is increased in various conditions such as liver disease, siderable prognostic value in AIDS and adult T-cell tuberculosis, typhoid, infective mononucleosis and cer- leukaemia (ATL) cases [5, 6]. tain malignancies, especially those of haematopoietic origin. The origin of serum ADA and the mechanisms by which serum activities are increased have not been References fully elucidated. 1. Gakis C. Adenosine deaminase (ADA) isoenzymes ADA1 Whatever the biological role of ADA1 and ADA2, it and ADA2: diagnostic and biological role. Eur Respir has been demonstrated that the presence (low or high) J 1996; 632–633. of these isoenzymes in biological fluids has diagnostic 2.
    [Show full text]
  • Role of the HPRG Component of Striated Muscle AMP Deaminase in the Stability and Cellular Behaviour of the Enzyme
    biomolecules Review Role of the HPRG Component of Striated Muscle AMP Deaminase in the Stability and Cellular Behaviour of the Enzyme Francesca Ronca * and Antonio Raggi Laboratory of Biochemistry, Department of Pathology, University of Pisa, via Roma 55, 56126 Pisa, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-050-2218-273; Fax: +39-050-2218-660 Received: 19 July 2018; Accepted: 20 August 2018; Published: 23 August 2018 Abstract: Multiple muscle-specific isoforms of the Zn2+ metalloenzyme AMP deaminase (AMPD) have been identified based on their biochemical and genetic differences. Our previous observations suggested that the metal binding protein histidine-proline-rich glycoprotein (HPRG) participates in the assembly and maintenance of skeletal muscle AMP deaminase (AMPD1) by acting as a zinc chaperone. The evidence of a role of millimolar-strength phosphate in stabilizing the AMPD-HPRG complex of both AMPD1 and cardiac AMP deaminase (AMPD3) is suggestive of a physiological mutual dependence between the two subunit components with regard to the stability of the two isoforms of striated muscle AMPD. The observed influence of the HPRG content on the catalytic behavior of the two enzymes further strengthens this hypothesis. Based on the preferential localization of HPRG at the sarcomeric I-band and on the presence of a Zn2+ binding motif in the N-terminal regions of fast TnT and of the AMPD1 catalytic subunit, we advance the hypothesis that the Zn binding properties of HPRG could promote the association of AMPD1 to the thin filament. Keywords: AMP deaminase (AMPD); histidine-proline-rich glycoprotein (HPRG); striated muscle; Troponin T (TnT) 1.
    [Show full text]
  • STRIPE2 Encodes a Putative Dcmp Deaminase That Plays an Important Role in Chloroplast Development in Rice
    Available online at www.sciencedirect.com ScienceDirect JGG Journal of Genetics and Genomics 41 (2014) 539e548 ORIGINAL RESEARCH STRIPE2 Encodes a Putative dCMP Deaminase that Plays an Important Role in Chloroplast Development in Rice Jing Xu a, Yiwen Deng a, Qun Li a, Xudong Zhu b,*, Zuhua He a,* a National Key Laboratory of Plant Molecular Genetics and National Center of Plant Gene Research, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai 200032, China b China National Rice Research Institute, Hangzhou 31006, China Received 31 March 2014; revised 8 May 2014; accepted 9 May 2014 Available online 19 June 2014 ABSTRACT Mutants with abnormal leaf coloration are good genetic materials for understanding the mechanism of chloroplast development and chlorophyll biosynthesis. In this study, a rice mutant st2 (stripe2) with stripe leaves was identified from the g-ray irradiated mutant pool. The st2 mutant exhibited decreased accumulation of chlorophyll and aberrant chloroplasts. Genetic analysis indicated that the st2 mutant was controlled by a single recessive locus. The ST2 gene was finely confined to a 27-kb region on chromosome 1 by the map-based cloning strategy and a 5-bp deletion in Os01g0765000 was identified by sequence analysis. The deletion happened in the joint of exon 3 and intron 3 and led to new spliced products of mRNA. Genetic complementation confirmed that Os01g0765000 is the ST2 gene. We found that the ST2 gene was expressed ubiquitously. Subcellular localization assay showed that the ST2 protein was located in mitochondria. ST2 belongs to the cytidine deaminase-like family and possibly functions as the dCMP deaminase, which catalyzes the formation of dUMP from dCMP by deamination.
    [Show full text]
  • Purine Nucleoside Phosphorylase, Or Adenosine Deaminase (Lesch-Nyhan Syndrome/Immunodeficiency) L
    Proc. Natl. Acad. Sci. USA Vol. 75, No. 8, pp. 3722 -3726, August 1978 Biochemistry Purine metabolism in cultured human fibroblasts derived from patients deficient in hypoxanthine phosphoribosyltransferase, purine nucleoside phosphorylase, or adenosine deaminase (Lesch-Nyhan syndrome/immunodeficiency) L. F. THOMPSON*, R. C. WILLIS*, J. W. STOOPt, AND J. E. SEEGMILLER* * Department of Medicine, University of California, San Diego, La Jolla, California 92093; and t University Children's Hospital, Het Wilhelmina Kinderziekenhuis, Nieuwe Gracht 137, Utrecht, The Netherlands Contributed by J. Edwin Seegmiller, June 8, 1978 ABS14RACT Rates of purine synthesis de novo, as measured tive, high molecular weight form. Thus, either an increase in by the incorporation of [4C]formate into newly synthesized the concentration of PP-ribose-P or a decrease in the levels of purines, have been determined in cultured human fibroblasts derived from normal individuals and from patients deficient inhibitory nucleotides could potentially accelerate the rate of in adenosine deaminase, purine nucleoside phosporylase, or purine synthesis de novo and result in purine "overproduction." hypoxanthine phosphoribosyltransferase, three consecutive This communication concerns the study of purine metabolism enzymes of the purnne salvage pathway. All four types of cell in cultured human fibroblasts deficient in each of three en- lines are capable of incorporating [14C]formate into purines at zymes of the purine salvage pathway and attempts to define approximately the same
    [Show full text]
  • Developmental Disorder Associated with Increased Cellular Nucleotidase Activity (Purine-Pyrimidine Metabolism͞uridine͞brain Diseases)
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 11601–11606, October 1997 Medical Sciences Developmental disorder associated with increased cellular nucleotidase activity (purine-pyrimidine metabolismyuridineybrain diseases) THEODORE PAGE*†,ALICE YU‡,JOHN FONTANESI‡, AND WILLIAM L. NYHAN‡ Departments of *Neurosciences and ‡Pediatrics, University of California at San Diego, La Jolla, CA 92093 Communicated by J. Edwin Seegmiller, University of California at San Diego, La Jolla, CA, August 7, 1997 (received for review June 26, 1997) ABSTRACT Four unrelated patients are described with a represent defects of purine metabolism, although no specific syndrome that included developmental delay, seizures, ataxia, enzyme abnormality has been identified in these cases (6). In recurrent infections, severe language deficit, and an unusual none of these disorders has it been possible to delineate the behavioral phenotype characterized by hyperactivity, short mechanism through which the enzyme deficiency produces the attention span, and poor social interaction. These manifesta- neurological or behavioral abnormalities. Therapeutic strate- tions appeared within the first few years of life. Each patient gies designed to treat the behavioral and neurological abnor- displayed abnormalities on EEG. No unusual metabolites were malities of these disorders by replacing the supposed deficient found in plasma or urine, and metabolic testing was normal metabolites have not been successful in any case. except for persistent hypouricosuria. Investigation of purine This report describes four unrelated patients in whom and pyrimidine metabolism in cultured fibroblasts derived developmental delay, seizures, ataxia, recurrent infections, from these patients showed normal incorporation of purine speech deficit, and an unusual behavioral phenotype were bases into nucleotides but decreased incorporation of uridine.
    [Show full text]
  • ADAR RNA Editing Below the Backbone
    Downloaded from rnajournal.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW ADAR RNA editing below the backbone LIAM KEEGAN, ANZER KHAN, DRAGANA VUKIC, and MARY O’CONNELL CEITEC at Masaryk University Brno, Pavilion A35, Brno CZ-62500, Czech Republic ABSTRACT ADAR RNA editing enzymes (adenosine deaminases acting on RNA) that convert adenosine bases to inosines were first identified biochemically 30 years ago. Since then, studies on ADARs in genetic model organisms, and evolutionary comparisons between them, continue to reveal a surprising range of pleiotropic biological effects of ADARs. This review focuses on Drosophila melanogaster, which has a single Adar gene encoding a homolog of vertebrate ADAR2 that site-specifically edits hundreds of transcripts to change individual codons in ion channel subunits and membrane and cytoskeletal proteins. Drosophila ADAR is involved in the control of neuronal excitability and neurodegeneration and, intriguingly, in the control of neuronal plasticity and sleep. Drosophila ADAR also interacts strongly with RNA interference, a key antiviral defense mechanism in invertebrates. Recent crystal structures of human ADAR2 deaminase domain–RNA complexes help to interpret available information on Drosophila ADAR isoforms and on the evolution of ADARs from tRNA deaminase ADAT proteins. ADAR RNA editing is a paradigm for the now rapidly expanding range of RNA modifications in mRNAs and ncRNAs. Even with recent progress, much remains to be understood about these groundbreaking ADAR RNA modification systems. Keywords: ADAR; Drosophila melanogaster; RNA editing; dsRNA; RNA modification; epitranscriptome INTRODUCTION tion detected by standard RNA-seq. Therefore, studies on ADAR RNA editing began much earlier and they now also ADARs: promiscuous and site-specific RNA editing lead the way toward understanding the effects of a range of other enzymatic modifications that have been found more re- ADARs (adenosine deaminases acting on RNA) were dis- cently in mRNA (O’Connell et al.
    [Show full text]